Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Clearmind Medicine Inc. (CMND : NSDQ)

• Company Description    Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Clearmind Medicine Inc. is based in VANCOUVER. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $1.02 Daily Weekly Monthly 20 Day Moving Average: 35,572 shares Shares Outstanding: 4.27 (millions) Market Capitalization: $4.35 (millions) Beta: 0.97 52 Week High: $2.18 52 Week Low: $0.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -1.76% 12 Week 18.60% 7.73% Year To Date -26.09% -32.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101-1220 WEST 6TH AVENUE - VANCOUVER,A1 V6H1A5 CAN ph: - fax: - invest@clearmindmedicine.com http://www.clearmindmedicine.com

• General Corporate Information    Officers Adi Zuloff-Shani - Chief Executive Officer Amitay Weiss - Chairman of the Board of Director Alan Rootenberg - Chief Financial Officer Yehonatan Shachar - Director Oz Adler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 185053402 SIC: 2834 Fiscal Year Fiscal Year End: October Last Reported Quarter: 07/01/25 Next Expected EPS Date: 01/28/26 Share - Related Items Shares Outstanding: 4.27 Most Recent Split Date: 11.00 (0.03:1) Beta: 0.97 Market Capitalization: $4.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 01/28/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.89 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 57.63% vs. Previous Quarter: -56.25% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 07/31/25 - -147.22 04/30/25 - -164.79 01/31/25 - -140.87 ROA 07/31/25 - -63.96 04/30/25 - -71.12 01/31/25 - -64.28 Current Ratio 07/31/25 - - 04/30/25 - 1.74 01/31/25 - 1.72 Quick Ratio 07/31/25 - - 04/30/25 - 1.74 01/31/25 - 1.72 Operating Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Net Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Pre-Tax Margin 07/31/25 - - 04/30/25 - - 01/31/25 - - Book Value 07/31/25 - - 04/30/25 - 0.54 01/31/25 - 0.67 Inventory Turnover 07/31/25 - - 04/30/25 - - 01/31/25 - - Debt-to-Equity 07/31/25 - - 04/30/25 - 0.00 01/31/25 - 0.00 Debt-to-Capital 07/31/25 - - 04/30/25 - 0.00 01/31/25 - 0.24

Powered by Zacks Investment Research ©